ArticleJCO oncology advances2025
Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II Trial.
Article in JCO oncology advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting TROP2 and Exploiting AUNIP as a Determinant of ADC Cytotoxicity and Chemosensitivity in HNSCC and ESCA Cancers.Molecular carcinogenesis · 2026Article
- Causative Role for a BRCA2 Germline Pathogenic Variant in External Auditory Canal Squamous Cell Carcinoma.Genes, chromosomes & cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeImpaired homologous recombination-mediated DNA repair is common in head and neck squamous cell carcinoma (HNSCC) and in preclinical models and sensitizes HNSCC to poly (ADP-ribose) polymerase (PARP) inhibitors and platinum therapy. PARP inhibitors and anti-PD-1 antibodies have synergistic antitumor activity. The primary hypothesis of this phase II trial was that olaparib, a PARP inhibitor, given with pembrolizumab and carboplatin as first-line treatment for biomarker-unselected recurrent or metastatic (RM)-HNSCC, would result in a higher objective response rate (ORR) than that historically reported with fluorouracil, pembrolizumab, and platinum therapy.
methodsPatients received up to six 21-day cycles of olaparib (200 mg twice daily orally on days 1-10), pembrolizumab, and carboplatin followed by 29 cycles of olaparib (300 mg twice a day on days 1-21) and pembrolizumab. The primary end point was independent radiologist-assessed confirmed objective response per RECIST v1.1. A Simon optimal two-stage design tested the null (H
resultsBetween July 08, 2021, and October 11, 2023, 30 patients were enrolled. Among the 29 evaluable patients, the ORR was 51.7% (90% CI, 35.2 to 68.0;
conclusionOlaparib, pembrolizumab, and carboplatin given as first-line treatment of RM-HNSCC resulted in a higher ORR than that historically reported with fluorouracil, pembrolizumab, and platinum therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.